Abstract
Klaus Jensen* speaks to Daphne Boulicault, Commissioning Editor: A Copenhagen native, Klaus Henning Jensen started his career working as a medical doctor in a hospital setting. An entrepreneur at heart, he drew from his background in physics and business administration to co-found a device company – successfully developing a new type of surgical screw for osteosynthesis of hip fractures. Klaus’ career at Novo Nordisk spans almost a decade and is rooted in Global Medical Affairs. He has held a series of Medical Director and Vice President roles with responsibilities cutting across the entire Novo Nordisk (UK and Ireland) diabetes portfolio – medical devices, Victoza®(liraglutide), Tresiba®(insulin degludec), Ryzodeg® (insulin degludec/insulin aspart) and Xultophy® (insulin degludec/liraglutide), as well as other GLP-1 and insulin treatments – with medical and scientific responsibility for the R&D of several of these products. He now sits on the UK & Ireland leadership team as Head of Clinical, Medical and ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
